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Port site metastases after pelvic and para-aortic laparoscopic lymphadenectomy staging in cervix cancer. Case
report
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Background. Patients diagnosed with locally advanced cervical cancer need a correct evaluation of lymph node. The presence of
lymph node metastases is an important prognostic factor, which will determine the extent of the radiation ﬁeld. Surgical staging
by pelvic and aortocava laparoscopic lymphadenectomy is more accurate than clinical staging.
Objective. To report a case of squamous cell Cervix IVB carcinoma with metastases at the trocar site following laparoscopic
lymphadenectomy staging.
Case report. A 65 year old woman diagnosed with squamous cell Cervix carcinoma G3, with both parametrial involvement, FIGO
2008 stage IIB, and IVB after pelvic and para-aortic laparoscopic lymphadenectomy staging. PET CT at diagnosis showed lymph
node involvement in the right external iliac chain. Paraortic nodes were not involved. The patient underwent Helical Tomother-
apy IMRT including: Vagina, cervix, paracolpios, parametrium, ovaries, pelvic nodal areas (iliac, obturator, presacral, bilateral
paraortic and inguinal), up to a total dose 50.4Gy with a simultaneous boost of 57.96Gy to pathological pelvic adenopathies.
Subsequently, the patient received PDR Braquitherapy (30Gy) with a vagino–uterine applicator A PET-CT performed six months
after showed a soft tissue density nodule (1.6×1 cm) between muscle planes of the abdominal left wall, which seems to cor-
respond in physical examination with a palpable induration of 1–2 cm under scar laparoscopy. FNA conﬁrmed the presence of
subcutaneous metastases of Cervical Cancer. The patient underwent surgery resection of the nodule following by External Beam
Radiation Therapy on tumor bed up to a total dose 50Gy.
Conclusion. One of the problems of laparoscopic lymphadenectomy is the tumor seeding at the trocar portals, and although the
frequency is unknown, it has been reported in both gynecological tumors (ovary, cervix) and no gynecological (gallbladder, kidney,
colon, stomach).
http://dx.doi.org/10.1016/j.rpor.2013.03.236
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Purpose/Objective. The aim of this study was to evaluate the qualitative response using post-therapy molecular imaging with [18F]
Fluorodeoxyglucose (FDG) PET/CT and to compare it with clinical response in patients with locally advanced cervical carcinoma
treated with radio-chemotherapy followed by brachytherapy.
Material and methods. This was a prospective cohort study of 27 patients with stage IB2-stage IIIB with new diagnosis of cervical
carcinoma who underwent pre- and post-treatment whole-body FDG-PET/CT. All patients were treated with external beam radio-
therapy and concurrent chemotherapy followed by high-dose rate (HDR) brachytherapy between August 2009 and August 2012.
Median age was 50 years (31–79). Post-therapy FDG-PET/CT was performed with a median of 13 weeks (11–20) after completing
brachytherapy. The qualitative results persistent or negative of PET/CT pre and post-therapy were recorded by 2 independent
observers and correlated with clinical response at the same time. Median follow-up was 19 months (7–33).
Results. Clinical assessment after treatment showed complete response in 18/27, local persistence in 1/27 and partial response
in 8/27. The post-therapy PET/CT showed persistent FDG uptake in 7/27 and was negative in 20 cases. 1/7 persistent uptake
correlated well with clinical ﬁndings, while 3/7 still showed partial response and the remaining 3, complete response. In 2 cases
PET/CT showed new sites of increased FDG uptake that were distant metastases. One of them presented negative uptake in
cervix whereas the other one had persistent uptake in cervix.
Conclusion. FDG-PET is a valuable tool to evaluate local response, correlates well with clinical ﬁndings. Post-therapy persistent
FDG uptake might be predictive of clinical persistent loco regional disease and can detect unsuspected distant metastases.
Increasing evidence has documented the value of FDG-PET/CT in Oncology, but only limited data comparing PET ﬁndings pre
and post-treatment with clinical response in patients with cervical carcinoma is available.
http://dx.doi.org/10.1016/j.rpor.2013.03.237
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Introduction/Purpose. Primary vaginalmelanoma is rare, but biologically aggressive. It affects elderlywomen and represents almost
3% of all vaginal tumors and about 1% of melanoma diagnosed in women. Its estimated incidence is 0.026 per 100,000 women a
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year. Tumor size is the strongest predictor of survival. Surgery is the treatment of choice in early disease stage. In local advanced
stages, radiotherapy associated or not to chemotherapyhas beenused.Wepresent a case treatedwith external beamradiotherapy
and interstitial brachytherapy.
Material and methods. A gynecological examination performed to an 81 year old woman with vaginal bleeding and local pain
revealed a tumor mass attached to the anterior and lateral walls of the vagina and coming out the introitus. MRI and PET-
CT revealed a 6.4 cm tumor mass in the upper third of the vagina embracing the urethral septum without metastases. Biopsy
conﬁrmed malignant primary vaginal melanoma. She underwent external beam radiotherapy to the pelvis, receiving a total dose
of 46Gy, followed by interstitial brachytherapy with high dose rate (HDR) up to a 60Gy total dose.
Results. Six months later, a reduction of 3 cm in tumor size was observed on physical examination, conﬁrmed by MRI/PET-TC; 12
months clinical and repeated imaging demonstrated persistent disease in the anterior wall of the vagina on urethral meatus.
No symptom of vaginal bleeding was reported, but local pain was not controlled and patient was referred to Pain Unit. No acute
urinary or rectal toxicity were observed. The patient died 14 months later.
Conclusions. Local excision is the treatment of choice in early disease but most patients are diagnosed at advanced stage. A
combination of EBRT and interstitial brachytherapy is a reasonable treatment, but tumor size is a limitation to local control this
vagina melanoma.
http://dx.doi.org/10.1016/j.rpor.2013.03.238
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Purpose and objective. Elevation of the SCC in early cervical cancer is associated with nodal and lymphovascular inﬁltration, and is
regarded as a marker for the need of treatment- chemo and/or radiotherapy (RT)- and poor prognosis. In this study we analyzed
SCC value as a prognostic factor before chemo-RT treatment and after completion.
Materials and methods. We followed a cohort of 236 patients from 1999 to 2011, under a weekly scheme with IV cisplatin (40mg/m2)
and concomitant RT. FIGO stage distribution was as follows: 7 (IB1), 27 (IB2), 2 (IIA), 73 (IIB), 1 (IIIA), 109 (IIIB), 17 (IVA). The SCC at
diagnosis was elevated above the cutoff point (1.5 or 2.5ng/ml) in 160 (67.8%) patients and was considered normal in 76 (32.2%).
Themeanvalues of SCC for different FIGO stageswere: IB1=1.04, IB2=5.36, IIA=0.55, IIB = 13.86, IIIA=31.80, IIIB = 20.03, IVA=34.75
(p<0.0001). The mean value amongst patients with elevated SCC, was 22.5 (r: 1.7–235, p25=4.8, p50=11.4, p75=22.4). In order to
assess SCC values at diagnosis (SCCD), we grouped patients according to their initial values: SCCD0=normal SCC, SCCD1=high
SCC -up to the value of percentile 50- (<11.4) and SCCD2=SCC≥11.4. At the end of the chemo-RT, clinical response was assessed
by physical examination (PE) and the value of SCC: PE was normal in 188 patients reﬂecting complete clinical response (CR); a
partial response (PR) over 50% was observed in 47 patients, and 1 patient remained with stable disease (SD); SCC was normal in
214 patients (SCCT0) and remained elevated in 20 (SCCT1). SCC was not performed in only 2 patients. When grouping patients
according to their combination of SCC and clinical response at the end of treatment, we obtained the following prognosis groups
(PG): PG0 (CR and normal SCC, n=173 patients), PG1 (CR and high SCC, n=14), PG2 (PR and normal SCC, n=41) and PG3 (SD and
high SCC, n=6).
Results. The mean follow-up-time was 55 months. An overall 5 year (SG5) survival using actuarial method (SG5) was found at
72.3%, with 67 deaths occurring in the following period. No statistical differences in SG5 were found between patients with
normal or elevated SCC at diagnosis, but the grouped analysis-according to SCCD- showed differences among SCCD0, SCCD1
and SCCD2 groups with values 76.2%, 86% and 57.5% respectively (p=0.0006). SG5 between SCCT1 and SCCT0 patients was 70.3%
and 25% respectively (p<0.0001), and for those with CR and PR, SG5 was 76.2% and 58.3% (p<0.0001). Finally, the SG5 in patients
PG0, PG1, PG2, PG3 was: 79.3%, 47.1%, 64.8%, and 16% respectively (p<0.0001).
Conclusions. SG5 showed to be similar amongst patients with normal and elevated SCC at diagnosis; however, an SCC value above
11.4ng/ml, showed to have worse results.
http://dx.doi.org/10.1016/j.rpor.2013.03.239
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Introduction. The treatment of locally advanced cervical carcinoma (LACC) is concomitant chemoradiation followed by brachyther-
apy or surgery as the answer reached. The objective is know our results in terms of overall survival (OS), disease-free
survival (DFS), relapse-free survival (RFS), metastasis-free survival (MFS) and toxicity (RTOG) of patients with LACC treated with
radiochemotherapy.
Material and methods. Between 1998 and June-2012, 107 patients, mean age 55±13 (25–83), were analyzed retrospectively. Distri-
bution by stages (FIGO): Ib2=10.3%, IIa = 17.8%, IIb = 31.8%, IIIa = 3.7% IIIb = 29.9% and IVA=6.6%. Histologically, 88% epidermoid
